TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05117242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV
Study: NCT05469516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merz Radiesse Injectable Implant
Description: Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
Study: NCT04851782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivEAD tubing kit
Description: ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivEAD tubing kit
Description: ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
Study: NCT04984889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-662
Description: Lyophilized, sterile concentrate of human protein C
Study: NCT06671353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video decision aid
Description: video decision aid for advance care planning
Study: NCT04083170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dilanubicel
Description: Given IV
Study: NCT04502394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: acalabrutinib is a BTK inhibitor anticancer drug taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
Study: NCT04983004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation
Description: According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bedside rehabilitation
Description: The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
Study: NCT06690242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: MT1013 is a novel calcimimetic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: MT1013 is a novel calcimimetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etelcalcetide Hydrochloride
Description: the already-marketed therapeutic agents

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The measure does not contain the active ingredients
Study: NCT06692998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
Study: NCT05230069

Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed post an emergency call and evaluation.
Study: NCT05791669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish
Description: It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
Study: NCT06579287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ002
Description: Topical ophthalmic
Study: NCT06692998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
Study: NCT05659459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN001
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KIN001-Placebo
Description: Comparator - Oral tablet with same appearance of KIN001
Study: NCT06700252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: This intervention used gaze stabilization, habituation, balance training and exertional training. Exercises utilized included visual tracking, gaze holding with head turns, saccades, visual accommodation exercises, visual convergence exercises, positional accommodation, rockerboard proprioception, single leg balance on the floor and on dynamic surfaces, tandem balance on the floor and on dynamic surfaces, double leg balance on dynamic surfaces, mirror feedback of functional activities, and physical exertion training with walking, biking or sport specific activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Protocol
Description: This intervention symptom management and graduated return to physical activity involving a stepwise progression in which the participant proceeded to the next step if symptom-free at the current step for a 24-hour period. If any symptoms occurred at that step, the participant was returned to the previous step and tried to progress again after 24 hours of rest. The steps were as follows: 1) Patient to return to regular activities such as school 2) Light aerobic activity to increase the patient's heart rate achieved with 5 to 10 minutes on a stationary bike or walking but without weightlifting 3) Moderate activity which increased the heart rate with head or body movement that may have included sport specific exercise with minimal-moderate resistance 4) Heavy, non-contact activity in three planes of movement 5) Full contact practice 6) Competition
Study: NCT06699628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL757
Description: IRL757 capsules
Study: NCT06579287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Topical ophthalmic
Study: NCT04819438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg Oral Film
Description: Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilutek 50Mg Tablet
Description: One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
Study: NCT04875507

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychology
Description: This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
Study: NCT05908071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 capsule
Description: Capsule administered orally after meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Capsule administered orally after meals.
Study: NCT05568914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry
Description: Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-electrical Impedance Analysis (BIA)
Description: Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional assessments
Description: The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
Study: NCT05132998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program
Description: In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community exercise intervention
Description: In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
Study: NCT05132257

Intervention type: PROCEDURE
Intervention: Severe ROP
Description: The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
Study: NCT06148740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Health Pro Vitality Daily Restorative Face Serum with Propolis & Vitamin C
Description: Skin serum containing propolis, vitamin C, and manuka honey.
Study: NCT05296460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone gel
Description: The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
Study: NCT06387810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome II combined with 5-FU/LV and oxaliplatin
Description: irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs.
Study: NCT06553716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess
Description: The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess
Description: The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
Study: NCT06059872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
Study: NCT05689606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise includes acute high-intensity interval training.
Study: NCT05320094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal with Sorbitol
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal with Sorbitol
Description: Specified dose on specified days
Study: NCT05646407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honeywell HT-900 Turbo Force Air Circulator
Description: This is a basic, portable, household fan with a single cost of CDN$21.99.
Study: NCT06490718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: USG ESPB
Description: After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure.
Study: NCT06428565

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) or cold laser therapy
Description: Low-level laser therapy (LLLT) or cold laser therapy
Study: NCT05724160

Intervention type: OTHER
Group type: OTHER
Intervention: Using sitting ellipticals
Description: Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy Protocol
Description: Routine physiotherapy protocol

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy Protocol
Description: Routine physiotherapy protocol
Study: NCT05749003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensorimotor training exercise
Description: Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy program of exercise.
Description: stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program of exercise.
Description: stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
Study: NCT06390410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: 100 mg PTI-125
Study: NCT05068557

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).
Description: Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
Study: NCT06390410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: 100 mg PTI-125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: 100 mg PTI-125
Study: NCT04118036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenously over 30 minutes every 21 days (+/- 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenously over 30 minutes every 21 days (+/- 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral 2 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral 2 times a day
Study: NCT06264141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide Releasing Solution
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray with isotonic saline
Description: The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
Study: NCT06204692

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dental implant
Description: consisted of 6 patients where computer guided dental implant placement
Study: NCT04881500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Patients will follow motivational interview (2 individual sessions by phone)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Patients will follow routine care
Study: NCT05055258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: KVD824 300 mg Modified-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: KVD824 300 mg Modified-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: KVD824 300 mg Modified-Release Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KVD824
Description: Placebo to KVD824 300 mg Modified-Release Tablets
Study: NCT05712304

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: second examination of the proximal colon
Description: For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
Study: NCT06404372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demetech Barbed PDO Suture
Description: The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
Study: NCT06212505

Intervention type: OTHER
Intervention: blood test
Description: blood test at the inclusion 10 tubes of 2.7mL blood
Study: NCT04538274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-driven intervention
Description: Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
Study: NCT04657380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN-e-PSY mobile application
Description: The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
Study: NCT05173688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h